Indications
Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
Composition
- Active substance
- ganaxolone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ztalmy
- Active substance
- ganaxolone
- ATC code
- N03AX
- Group
- Nervous system
- Therapeutic area
- Epileptic Syndromes, Spasms, Infantile
- Marketing authorisation holder
- Marinus Pharmaceuticals Emerald Limited
- Status
- Authorised